Cellectis S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on August 6, 2026, by Cellectis S.A., a foreign private issuer based in Paris, France, incorporates by reference the company's interim report for the six-month period ended June 30, 2026 (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided filing text serves as a cover sheet and does not contain specific financial data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document. The filing text does not provide a clear value for these metrics.
Material Changes
No material changes versus the prior comparable period are detailed in the provided text, as the specific interim report content is referenced but not included.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, risks, contingencies, or unusual items. These details are contained within the referenced Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Interim Report for the six months ended June 30, 2026) for actual financial performance data.
- Verify the status of the registration statements on Form F-3 and Form S-8 referenced for incorporation by reference.
- Confirm the company's liquidity position and cash burn rate in the full interim report, as this is critical for a biotechnology firm.
- Check for any updates on clinical trial progress or regulatory milestones not summarized in this cover sheet.